A major bivalent COVID-19 vaccine induces production of neutralizing antibodies against the coronavirus that circulated at the start of the pandemic as well as subvariants of omicron, albeit less ...

Brazilian scientists conducted the first research project to evaluate the immunity induced in an actual group of vaccinated ...

Vaccines Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global COVID-19 Vaccines Market to Reach 4.2 Billion Doses by 2025 The global market ...

Q4 2023 Earnings Call Transcript April 24, 2024 CureVac N.V. isn’t one of the 30 most popular stocks among hedge funds at the ...

The ministry also encouraged all who are aged 6 months and above to get vaccinated a year after their last dose. Read more at ...

This is in response to a recent local study that found two doses of mRNA vaccines provide enough protection. Read more at ...

The VDH reported last week that COVID-19 hospitalizations were at a statewide total of 3, which is the lowest they've been in ...

CureVac continues to advance its clinical development programs in prophylactic vaccines in collaboration with GSK. All currently tested candidates apply modified mRNA and are based on CureVac’s ...

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents ...

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the ...

GSK said in the lawsuit , opens new tab that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the ...

By Blake Brittain (Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in ...